<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957954</url>
  </required_header>
  <id_info>
    <org_study_id>V001</org_study_id>
    <secondary_id>R01EY021797</secondary_id>
    <nct_id>NCT03957954</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Limbal Stem Cell Deficiency</brief_title>
  <official_title>Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I study will collect preliminary information on the activity and safety of cLSC.
      We will investigate the ability to manufacture and transplant cLSC onto the cornea
      successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular
      surface (efficacy) without serious adverse events (safety).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 patients with severe to total Limbal Stem Cell Deficiency (LSCD) in one eye attributable
      to injury or ocular surgery. The first 5 eyes will receive the cLSCs to determine the
      feasibility and safety. Then the subsequent 15 eyes will be randomized into cLSC group and a
      scleral lens treatment (SCL) control group in a 2:1 ratio in blocks of 3 or 6 using a random
      number generator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of cLSC Transplant pertaining to Infection and/or Corneal Perforation</measure>
    <time_frame>12 months for all participants</time_frame>
    <description>Safety assessed by incidence of Serious Adverse Events (SAEs) directly related to cLSC: infection and/or corneal perforation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of cLSC Transplant pertaining to Manufacturing meeting Release Criteria</measure>
    <time_frame>12 months for all participants</time_frame>
    <description>Feasibility assessed by successful manufacturing of cLSC from biopsy that meets release criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of cLSC Transplant pertaining to Manufacturing without Contamination</measure>
    <time_frame>12 months for all participants</time_frame>
    <description>Feasibility assessed by successful cLSC manufacturing without contamination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Area of Corneal Epithelial Defect</measure>
    <time_frame>At 6 months and 12 months in both cLSC and the control groups</time_frame>
    <description>Evaluate changes in the area of corneal epithelial defect (ED) or lack of ED.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Clinical Score</measure>
    <time_frame>At 6 months and 12 months in both cLSC and the control groups</time_frame>
    <description>Evaluate changes in the clinical score determined by slit lamp examination using fluorescein staining and confocal imaging.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Limbal Stem-cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Cultivated Limbal Stem-Cells (cLSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scleral Contact Lens Device (SCL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cLSC</intervention_name>
    <description>Transplantation of cLSC</description>
    <arm_group_label>Cultivated Limbal Stem-Cells (cLSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scleral contact lens (SCL)</intervention_name>
    <description>Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.</description>
    <arm_group_label>Scleral Contact Lens Device (SCL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          1. Male or female ≥18 years of age.

          2. Best corrected visual acuity in the affected eye of 20/200 or less.

          3. Documentation of a LSCD diagnosis and the central cornea is affected.

          4. Absence of lagophthalmos and eyelid abnormality

          5. Adequate forniceal depth is ≥ 5 mm.

          6. LSCD fails to resolve by surgical treatments of the ocular surface during the previous
             6 months of screening visit.

          7. If the etiology of LSCD is due to chemical injury, a minimal interval of 1 year since
             the initial chemical injury is required.

          8. A Schirmer test result at 5 minute of ≥5 mm of wetting.

          9. Absence of active infectious keratitis in either eye at the Enrollment Visit.

         10. Have a life expectancy ≥ 2 years after enrollment.

        Main exclusion Criteria:

          1. Pregnant, breastfeeding, or unwilling to practice birth control during participation
             in the study.

          2. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data.

          3. Exposure keratopathy or lagophthalmos of the study eye.

          4. Persistent severe ocular surface inflammation and/or meibomian gland dysfunction

          5. Chemical injury occurred less than 12 months ago.

          6. Presence of ocular surface tumor.

          7. Uncontrolled diabetes with last hemoglobin A1C (HgA1C) &gt;8.5.

          8. Presence of known allergies to any of the cLSC components.

          9. Current participation in another simultaneous medical investigation or trial.

         10. Unable to be compliant with or complete the requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Deng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stein Eye Institute UCLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemence Bonnet, MD</last_name>
    <phone>310-794-7813</phone>
    <email>CBonnet@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niree Dingizian</last_name>
    <email>NDingizian@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemence Bonnet, MD</last_name>
      <phone>310-794-7813</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Sophie Deng, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

